Seminars in Oncology Nursing
Volume 22 , Pages 10-19 , February 2006

Clinical Experience With Anti-EGFR Therapy

  • Anne Fish-Steagall

      Affiliations

    • Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • Peachtree Hematology/Oncology Consultants, Atlanta, GA
    • Yale Comprehensive Cancer Center, New Haven, CT
    • Corresponding Author InformationAddress correspondence to Anne Fish-Steagall, BS, RN, OCN®, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599
    • ,
  • Polly Searcy

      Affiliations

    • Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • Peachtree Hematology/Oncology Consultants, Atlanta, GA
    • Yale Comprehensive Cancer Center, New Haven, CT
    • ,
  • Rebecca Sipples

      Affiliations

    • Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • Peachtree Hematology/Oncology Consultants, Atlanta, GA
    • Yale Comprehensive Cancer Center, New Haven, CT

References 

  1. Herbst RS , Shin DM . Monoclonal antibodies to target epidermal growth factor receptor-positive tumors (A new paradigm for cancer therapy) . Cancer . 2002;94:1593–1611
  2. Brabender J , Danenberg KD , Metzger R , et al.   Epidermal growth factor receptor and HER2-neu mRNA expression in non–small cell lung cancer is correlated with survival . Clin Cancer Res . 2001;7:1850–1855
  3. Yarden Y , Sliwkowski MX . Untangling the ErbB signalling network . Nat Rev Mol Cell Biol . 2001;2:127–137
  4. Mendelsohn J . The epidermal growth factor receptor as a target for cancer therapy . Endocr Relat Cancer . 2001;8:3–9
  5. Harris M . Monoclonal antibodies as therapeutic agents for cancer . Lancet Oncol . 2004;5:292–302
  6. Herbst RS . Review of epidermal growth factor receptor biology . Int J Radiat Oncol Biol Phys . 2004;59(suppl):21–26
  7. Cunningham D , Humblet Y , Siena S , et al.   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer . N Engl J Med . 2004;351:337–345
  8. Saltz LB , Meropol NJ , Loehrer PJ , et al.   Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor . J Clin Oncol . 2004;22:1201–1208
  9. Fisher GA , Kuo T , Cho CD , et al.   A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer [abstract] . J Clin Oncol . 2004;22(suppl):3514
  10. Redlinger M , Kramer A , Flaherty K , et al.   A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer [abstract] . J Clin Oncol . 2004;22(suppl):3767
  11. Townsley C , Major P , Siu LL , et al.   Phase II study of OSI-774 in patients with metastatic colorectal cancer [abstract 179] . Eur J Cancer . 2002;38:S57
  12. Lenz HJ , Mayer RJ , Gold P , et al.   Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin [abstract 3510] . Proc Am Soc Clin Oncol . 2004;23:248
  13. Chung KY , Shia J , Kemeny NE , et al.   Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry . J Clin Oncol . 2005;23:1803–1810
  14. Saltz LB , Lenz H , Kindler H , et al.   Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer [abstract 169b] . Proc Am Soc Clin Oncol . 2005;
  15. Bonner JA , Giralt J , Harari PM , et al.   Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck (A phase III study of high dose radiation therapy with or without cetuximab [abstract]) . J Clin Oncol . 2004;22(suppl):5507
  16. Burtness BA , Li Y , Flood W , et al.   Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC) [abstract 901] . Proc Am Soc Clin Oncol . 2002;21:226a
  17. Trigo J , Hitt R , Koralewski P , et al.   Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) (Results of a phase II study [abstract]) . J Clin Oncol . 2004;22(suppl):5502
  18. Soulieres D , Senzer NN , Vokes EE , et al.   Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck . J Clin Oncol . 2004;22:77–85
  19. Fukuoka M , Yano S , Giaccone G , et al.   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer . J Clin Oncol . 2003;21:2237–2246
  20. Kris MG , Natale RB , Herbst RS , et al.   Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer . JAMA . 2003;290:2149–2158
  21. Giaccone G , Herbst RS , Manegold C , et al.   Gefitinib in combination with gemcitabine and cisplatin in advanced non–small-cell lung cancer (A phase III trial—INTACT 1) . J Clin Oncol . 2004;22:777–784
  22. Herbst RS , Giaccone G , Schiller JH , et al.   Gefitinib in combination with paclitaxel and carboplatin in advanced non–small-cell lung cancer (A phase III trial—INTACT 2) . J Clin Oncol . 2004;22:785–794
  23. Shepherd FA , Pereira J , Ciuleanu TE , et al.   A randomized placebo-controlled trial of erlotinib in patients with advanced non–small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy (A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial [abstract]) . J Clin Oncol . 2004;22(suppl):7022
  24. Gatzemeier U , Pluzanska A , Szczesna A , et al.   Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non–small cell lung cancer (NSCLC) [abstract] . J Clin Oncol . 2004;22(suppl):7010
  25. Herbst RS , Prager D , Hermann R , et al.   TRIBUTE – A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non–small cell lung cancer (NSCLC) [abstract] . J Clin Oncol . 2004;22(suppl):7011
  26. Rosell R , Daniel C , Ramlau R , et al.   Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs (CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non–small-cell lung cancer (NSCLC) [abstract]) . J Clin Oncol . 2004;22(suppl):7012
  27. Clark GM , Zborowski D , Santabárbara P , et al.   Smoking history is more predictive of survival benefit from erlotinib for patients with non–small cell lung cancer (NSCLC) than EGFR expression [abstract 7033] . Proc Am Soc Clin Oncol . 2005;
  28. Paez JG , Jänne PA , Lee JC , et al.   EGFR mutations in lung cancer (Correlation with clinical response to gefitinib therapy) . Science . 2004;304:1497–1500
  29. Lynch TJ , Bell DW , Sordella R , et al.   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib . N Engl J Med . 2004;350:2129–2139
  30. LoRusso PM . Phase I studies of ZD1839 in patients with common solid tumors . Semin Oncol . 2003;30(suppl 1):21–29
  31. Lenz HJ , Mayer RJ , Gold PJ , et al.   Activity of Erbitux (cetuximab) in patients with colorectal cancer refractory to a fluoropyrimidine, irinotecan, and oxaliplatin [abstract 225] . Proc Am Soc Clin Oncol . 2005;

 Supported in part by a grant from Bristol-Myers Squibb Company.

PII: S0749-2081(06)00034-9

doi: 10.1016/j.soncn.2006.01.011

Seminars in Oncology Nursing
Volume 22 , Pages 10-19 , February 2006

Article Tools